These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 35521719)
1. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances. Atar D; Langslet G; Tonstad S Kardiol Pol; 2022; 80(7-8):741-749. PubMed ID: 35521719 [TBL] [Abstract][Full Text] [Related]
2. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N BMJ; 2022 May; 377():e069066. PubMed ID: 35508320 [TBL] [Abstract][Full Text] [Related]
3. Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease. Gu J; Sanchez RJ; Chauhan A; Fazio S; Rosenson RS J Clin Lipidol; 2022; 16(6):901-905. PubMed ID: 36319536 [TBL] [Abstract][Full Text] [Related]
4. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699 [TBL] [Abstract][Full Text] [Related]
5. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965 [TBL] [Abstract][Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
7. [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?]. Katzmann JL; Laufs U Inn Med (Heidelb); 2022 Dec; 63(12):1316-1322. PubMed ID: 35391570 [TBL] [Abstract][Full Text] [Related]
8. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
14. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]
15. Safety Issues Associated With the Clinical Application of PCSK9 Inhibitors: Current Findings. Wang D; Zhang D Cardiol Rev; 2023 May-Jun 01; 31(3):155-161. PubMed ID: 35175957 [TBL] [Abstract][Full Text] [Related]
16. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491 [TBL] [Abstract][Full Text] [Related]
17. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061 [TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein cholesterol lowering treatment: the current approach. Crismaru I; Pantea Stoian A; Bratu OG; Gaman MA; Stanescu AMA; Bacalbasa N; Diaconu CC Lipids Health Dis; 2020 May; 19(1):85. PubMed ID: 32375792 [TBL] [Abstract][Full Text] [Related]
19. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? Cervelli N; Tocci G; Ferri C High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812 [No Abstract] [Full Text] [Related]